Xencor, Inc. has entered into a technology license and option agreement to provide Merck access to one of its Fc engineering patents for an undisclosed therapeutic monoclonal antibody, as well as an option to license the same IP for future products. Xencor will receive an upfront payment and annual maintenance fees. Xencor is also eligible to receive milestone payments and royalties on sales of any potential products that may result.   “This agreement with Merck reflects the significant va...